KAILA HARGIS: Open Payments
NPI 1750745964 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$740 in 24 payments from 10 companies in 2025. Trend: 2023 $162 · 2024 $515 · 2025 $740
Food & beverage: $740
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $258 |
| Amgen Inc. | 6 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| ABBVIE INC. | 3 | $47 |
| Neurocrine BioSciences, Inc. | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $29 |
| Almatica Pharma LLC | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $14 |
Products named: AIRSUPRA, REPATHA, TRINTELLIX, CAPLYTA, VRAYLAR, KRYSTEXXA, INGREZZA, Qelbree.
Industry payments across LA — which companies pay providers there.
